423 related articles for article (PubMed ID: 28408175)
1. An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer.
Seiler R; Oo HZ; Tortora D; Clausen TM; Wang CK; Kumar G; Pereira MA; Ørum-Madsen MS; Agerbæk MØ; Gustavsson T; Nordmaj MA; Rich JR; Lallous N; Fazli L; Lee SS; Douglas J; Todenhöfer T; Esfandnia S; Battsogt D; Babcook JS; Al-Nakouzi N; Crabb SJ; Moskalev I; Kiss B; Davicioni E; Thalmann GN; Rennie PS; Black PC; Salanti A; Daugaard M
Eur Urol; 2017 Jul; 72(1):142-150. PubMed ID: 28408175
[TBL] [Abstract][Full Text] [Related]
2. Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.
Clausen TM; Pereira MA; Al Nakouzi N; Oo HZ; Agerbæk MØ; Lee S; Ørum-Madsen MS; Kristensen AR; El-Naggar A; Grandgenett PM; Grem JL; Hollingsworth MA; Holst PJ; Theander T; Sorensen PH; Daugaard M; Salanti A
Mol Cancer Res; 2016 Dec; 14(12):1288-1299. PubMed ID: 27655130
[TBL] [Abstract][Full Text] [Related]
3. The specificity of the malarial VAR2CSA protein for chondroitin sulfate depends on 4-O-sulfation and ligand accessibility.
Spliid CB; Toledo AG; Sanderson P; Mao Y; Gatto F; Gustavsson T; Choudhary S; Saldanha AL; Vogelsang RP; Gögenur I; Theander TG; Leach FE; Amster IJ; Esko JD; Salanti A; Clausen TM
J Biol Chem; 2021 Dec; 297(6):101391. PubMed ID: 34762909
[TBL] [Abstract][Full Text] [Related]
4. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
5. Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.
Agerbaek MØ; Pereira MA; Clausen TM; Pehrson C; Oo HZ; Spliid C; Rich JR; Fung V; Nkrumah F; Neequaye J; Biggar RJ; Reynolds SJ; Tosato G; Pullarkat ST; Ayers LW; Theander TG; Daugaard M; Bhatia K; Nielsen MA; Mbulaiteye SM; Salanti A
Int J Cancer; 2017 Apr; 140(7):1597-1608. PubMed ID: 27997697
[TBL] [Abstract][Full Text] [Related]
6. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy.
Chen J; Wang L; Tang Y; Gong G; Liu L; Chen M; Chen Z; Cui Y; Li C; Cheng X; Qi L; Zu X
J Exp Clin Cancer Res; 2016 Jan; 35():2. PubMed ID: 26733306
[TBL] [Abstract][Full Text] [Related]
7. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
8. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract][Full Text] [Related]
9. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Baras AS; Gandhi N; Munari E; Faraj S; Shultz L; Marchionni L; Schoenberg M; Hahn N; Hoque MO; Berman D; Bivalacqua TJ; Netto G
PLoS One; 2015; 10(7):e0131245. PubMed ID: 26230923
[TBL] [Abstract][Full Text] [Related]
11. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.
Salanti A; Clausen TM; Agerbæk MØ; Al Nakouzi N; Dahlbäck M; Oo HZ; Lee S; Gustavsson T; Rich JR; Hedberg BJ; Mao Y; Barington L; Pereira MA; LoBello J; Endo M; Fazli L; Soden J; Wang CK; Sander AF; Dagil R; Thrane S; Holst PJ; Meng L; Favero F; Weiss GJ; Nielsen MA; Freeth J; Nielsen TO; Zaia J; Tran NL; Trent J; Babcook JS; Theander TG; Sorensen PH; Daugaard M
Cancer Cell; 2015 Oct; 28(4):500-514. PubMed ID: 26461094
[TBL] [Abstract][Full Text] [Related]
12. Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?
Schardt J; Roth B; Seiler R
World J Urol; 2019 Sep; 37(9):1759-1765. PubMed ID: 30392011
[TBL] [Abstract][Full Text] [Related]
13. Malaria Biomimetic for Tumor Targeted Drug Delivery.
Pihl J; Clausen TM; Zhou J; Krishnan N; Ørum-Madsen MS; Gustavsson T; Dagil R; Daugaard M; Choudhary S; Foged C; Esko JD; Zhang L; Fang RH; Salanti A
ACS Nano; 2023 Jul; 17(14):13500-13509. PubMed ID: 37435892
[TBL] [Abstract][Full Text] [Related]
14. JUND-dependent up-regulation of HMOX1 is associated with cisplatin resistance in muscle-invasive bladder cancer.
Peng Y; Chen Y; Chen S; Wang J; Jiang C; Hou W; Xu C
J Biochem; 2020 Jul; 168(1):73-82. PubMed ID: 32240302
[TBL] [Abstract][Full Text] [Related]
15. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
Goodspeed A; Jean A; Costello JC
Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
[TBL] [Abstract][Full Text] [Related]
16. Establishment and validation of a plasma oncofetal chondroitin sulfated proteoglycan for pan-cancer detection.
Zhang PF; Wu ZY; Zhang WB; He YQ; Chen K; Wang TM; Li H; Zheng H; Li DH; Yang DW; Zhou T; Deng CM; Liao Y; Xue WQ; Cao LJ; Li XZ; Zhang JB; Dong SQ; Wang F; Zheng MQ; Zhang WL; Mu J; Jia WH
Nat Commun; 2023 Feb; 14(1):645. PubMed ID: 36746966
[TBL] [Abstract][Full Text] [Related]
17. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).
Bunch B; Krishnan N; Greenspan RD; Ramakrishnan S; Attwood K; Yan L; Qi Q; Wang D; Morrison C; Omilian A; Bshara W; Pili R; Trump DL; Johnson C; Woloszynska A
Cell Cycle; 2019 Sep; 18(17):2055-2066. PubMed ID: 31318640
[TBL] [Abstract][Full Text] [Related]
18. A simple method for detecting oncofetal chondroitin sulfate glycosaminoglycans in bladder cancer urine.
Clausen TM; Kumar G; Ibsen EK; Ørum-Madsen MS; Hurtado-Coll A; Gustavsson T; Agerbæk MØ; Gatto F; Todenhöfer T; Basso U; Knowles MA; Sanchez-Carbayo M; Salanti A; Black PC; Daugaard M
Cell Death Discov; 2020; 6():65. PubMed ID: 32793395
[TBL] [Abstract][Full Text] [Related]
19. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of Trimodal Chemoradiotherapy with Cisplatin as a Bladder-Preserving Strategy for the Treatment of Muscle-Invasive Bladder Cancer.
Nagao K; Hara T; Nishijima J; Shimizu K; Fujii N; Kobayashi K; Kawai Y; Inoue R; Yamamoto Y; Matsumoto H; Matsuyama H
Urol Int; 2017; 99(4):446-452. PubMed ID: 28628910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
